The honest answer for most patients

For many patients researching knee cartilage treatment, the question is blunt: will this injection buy me time before surgery, or could it get me off the surgical list entirely?

For a defined group — those with a focal cartilage lesion in a mechanically stable joint, without bone-on-bone arthritis — the answer is yes to both possibilities. Published data across more than 19,000 procedures globally show functional improvements that are clinically meaningful and sustained over multiple years, and a meaningful proportion of patients who undergo the treatment do not go on to surgery within the follow-up periods reported.

The limit is important to state plainly: ChondroFiller™ is not a remedy for end-stage, bone-on-bone osteoarthritis. In that setting, no injectable treatment can substitute for joint replacement, and pursuing one instead risks delaying a necessary operation. Patient selection is the single most important variable in how this treatment performs.

On the evidence: no injectable — collagen scaffold or otherwise — has been tested in a randomised controlled trial with time-to-joint-replacement as its pre-specified primary endpoint. Any delay claim should therefore be read as biologically plausible and consistent with outcome data, not as a proven guarantee. That distinction matters most for patients weighing this option against a surgical referral they have already been offered.

Why ChondroFiller works differently from other knee injections

The distinction starts with biology. Most knee injections work above the cartilage surface — hyaluronic acid replenishes the synovial fluid that lubricates the joint, while corticosteroids dampen the inflammatory response driving pain. Both can bring meaningful short-term relief, but neither is designed to fill or repair the defect itself.

ChondroFiller™ works differently because it enters the defect rather than simply bathing the joint. Injected under real-time ultrasound guidance in an outpatient setting — no theatre, no general anaesthetic, no hospital admission — the liquid collagen Type I solution sets into a stable gel within minutes, forming a three-dimensional scaffold directly within the damaged area. It contains no donor or laboratory-grown cells; instead, progenitor cells from the surrounding synovium and subchondral bone migrate into the lattice and begin laying down new cartilage matrix. A 2025 ex vivo study confirmed this recruitment mechanism, recording a 2.4-fold increase in DNA content within the scaffold by day 14.

Matrix deposition continues over the following 6–24 months as the scaffold is progressively resorbed, with evidence suggesting the patient's own repair tissue ultimately replaces it entirely within one to two years. The aim, in other words, is structural change — addressing the defect — rather than temporary symptom cover.

This does not mean the outcome is certain; evidence suggests structural repair occurs in suitable patients, not that cartilage regrowth is guaranteed in every case. But the mechanism is categorically different from a lubricant or an anti-inflammatory.

What the clinical evidence actually shows

Across four published knee clinical studies, mean IKDC improvements consistently exceeded the 16.7-point minimal clinically important difference — the threshold above which a patient is likely to notice a meaningful change in everyday function. In a prospective post-market cohort by Jerosch et al., the mean gain was 32.4 IKDC points, sustained and slightly increased at three-year follow-up, with patients reaching a mean functional score of 80.1 out of 100. The IKDC (International Knee Documentation Committee) scale runs from 0 to 100; higher scores reflect better function and lower symptom burden.

MRI data add a structural dimension. European knee studies report MOCART scores of 81.6 to 84.3 — a validated MRI grading system in which 100 represents complete, well-integrated defect filling. Scores above 80 indicate that more than 80% of the defect has been filled and that the new tissue has integrated with surrounding cartilage. Published imaging also documents a maturation curve: MOCART rose from 65.3 at four weeks to 81.6 at twelve months in one series, confirming that structural repair continues progressively after the initial injection.

The first prospective randomised multicentre study comparing ChondroFiller with microfracture surgery (n=23) reported significant IKDC improvements at 3, 6, and 12 months with no adverse events. A notable secondary finding: six of the ten patients allocated to microfracture declined to undergo the procedure, suggesting that the prospect of even minor surgery weighs heavily for some patients when a non-surgical route is available.

The honest caveat is that key trial cohorts ran to between 13 and 26 patients, and long-term randomised controlled data remain limited compared with established surgical options. Published series indicate consistent benefit — they do not yet constitute the volume of evidence that decades of arthroplasty research provides.

Delaying surgery — how strong is the evidence?

The most concrete published benchmark for what 'delay' looks like in data comes not from ChondroFiller but from hyaluronic acid — and the scale is striking. A U.S. insurance claims analysis of 182,022 patients who eventually received a total knee replacement found that those who had received at least one course of HA injection waited a median of 484 days before surgery; patients who had received no injections waited a median of 114 days. That roughly 370-day gap does not mean HA prevented surgery — every patient in the dataset eventually had a replacement — but it establishes a real-world benchmark for the kind of postponement injectable treatments can produce in observational data.

No injection of any class, including collagen scaffolds, has used time-to-replacement as a primary endpoint in a randomised controlled trial. The delay argument for ChondroFiller rests on a different chain of reasoning: structural repair reduces pain, improved mechanics slow articular loading and progression, and functional score improvements sustained over three to five years collectively reduce the clinical urgency for an operation. That is a biologically coherent pathway, even where a direct RCT on the delay endpoint does not yet exist.

ChondroFiller has also been studied in hip joints, and that cohort offers longer follow-up data on the same patient-selection question. In a cohort of 26 patients followed for up to five years, 17 of 21 available patients achieved good or excellent results — a meaningful proportion who, by that measure, avoided replacement within the study window. Two patients did ultimately require total hip replacement. Critically, patients who entered the study with pre-existing advanced osteoarthritis (Tönnis grade 2–3) fared poorly — a finding that mirrors the patient-selection boundary the evidence consistently draws: the scaffold cannot compensate for cartilage that is no longer salvageable.

Who is likely to benefit — and who is not

The bone-on-bone exclusion is the clearest boundary. ChondroFiller is designed for focal cartilage defects — discrete areas of damage in an otherwise functional joint — not for diffuse, end-stage wear where the articular surface has gone entirely. Patients with generalised osteoarthritis at advanced imaging grades, or where imaging shows bone-on-bone contact, are unlikely to benefit; published series confirm that pre-existing advanced OA consistently undermines outcomes regardless of the treatment applied.

Those most likely to benefit present with a Grade III or IV focal lesion in a mechanically stable joint, with reasonable surrounding cartilage. Joint stability, BMI, activity demands, and prior treatments all form part of a clinical suitability picture that imaging and specialist review can clarify — this is not a decision that scans alone or patient self-assessment can resolve.

Two practical points are worth understanding before a consultation. First, a 2024 biomechanical study found that the scaffold does not protect the opposing cartilage surface during initial loading — not because the material fails, but because it requires time to stabilise within the defect. This is the evidence basis for the 4–6 week protected weight-bearing rehabilitation phase: a clinically grounded protocol, not an over-cautious precaution. Second, precision of placement matters. A wrist study showed that overfilling a defect produced fibrous tissue formation, while flush-level applications were complication-free — reinforcing why image-guided delivery is central to the technique.

For patients uncertain whether they fall within the suitable group, the appropriate next step is an assessment with current MRI imaging.

What happens after the injection — timeline and next steps

The post-injection period divides into three broad phases. The first — protected weight-bearing for four to six weeks, as established in the previous section — is necessary for scaffold stabilisation, not for wound healing; patients are upright and mobile, but load through the treated joint is restricted. This is also the phase in which least is felt: the biology is active, but symptom improvement typically lags behind structural change.

Functional gains, in published series, begin to emerge at three months and continue through six and twelve months — a trajectory that rewards patience. The scaffold does not function as an immediate analgesic; it operates on the timescale of tissue formation. Complete resorption of the collagen matrix, replaced by the patient's own regenerated tissue, takes place over one to two years.

One point worth carrying from any consultation: choosing this injection does not remove future options. Every surgical pathway — from cartilage repair to total knee replacement — remains available if the procedure does not deliver adequate benefit. This is not a bridge that burns.

For the right patient, a single outpatient appointment may realistically defer a major operation by years, or remove it from the picture altogether. For those whose joint disease has progressed beyond what any injectable can address, the same injection is unlikely to change that trajectory. Which side of that line a patient falls on is a clinical question — one that imaging and specialist review can answer. The assessment pathway is available at amsk.co.uk.

1. [1] Cartilage Reconstruction Using Chondrofiller in Intra-Articular Distal Radius Fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
2. [2] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
3. [3] Arthroscopic Utilization of ChondroFiller Gel for Hip Articular Cartilage Defects: 12–60 Month Follow-Up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] Controlled, Randomized Multicenter Study: ChondroFiller Liquid vs Microfracturing for Focal Knee Cartilage Defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1